Pål Rongved Selected Research

myxin

4/2021	New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells.
1/2017	Total synthesis and antileukemic evaluations of the phenazine 5,10-dioxide natural products iodinin, myxin and their derivatives.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pål Rongved Research Topics

Disease

4	Neoplasms (Cancer) 12/2019 - 07/2014
2	Hypoxia (Hypoxemia) 04/2021 - 01/2017
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2021
1	Infections 01/2020
1	Peritonitis 01/2020
1	Carcinoma (Carcinomatosis) 01/2018
1	Leukemia 01/2017
1	Colorectal Neoplasms (Colorectal Cancer) 07/2014
1	Atherosclerotic Plaque (Atheroma) 07/2014
1	Body Weight (Weight, Body) 01/2014

Drug/Important Bio-Agent (IBA)

2	myxinIBA 04/2021 - 01/2017
2	ProdrugsIBA 04/2021 - 07/2014
2	OxidesIBA 04/2021 - 01/2017
2	iodininIBA 04/2021 - 01/2017
1	phenazine di-N-oxideIBA 04/2021
1	Meropenem (Merrem)FDA LinkGeneric 01/2020
1	Carbapenems (Carbapenem Antibiotics)IBA 01/2020
1	CarbazolesIBA 12/2019
1	carbazoleIBA 12/2019
1	Peptides (Polypeptides)IBA 04/2019
1	Biological ProductsIBA 01/2018
1	Oxygen (Dioxygen)IBA 01/2017
1	asparaginylendopeptidase (legumain)IBA 07/2014
1	OxysterolsIBA 01/2014
1	Liver X ReceptorsIBA 01/2014
1	Triglycerides (Triacylglycerol)IBA 01/2014

Therapy/Procedure

1	Therapeutics 12/2019